Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bausch Health Companies (BHC)
NYSE:BHC
RESEARCH TOOLSreports
Bausch Health Companies (BHC) Stock Price & Analysis
2,366 Followers
BHC Stock Chart & Stats
Day’s Range$8.43 - $8.78
52-Week Range― - ―
Previous Close$8.66
Volume1.07M
Average Volume (3M)N/A
Market Cap
$3.14B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
$0.69Last Dividend Ex-Date
Nov 10, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.80Price Target Upside25.95% Upside
Rating ConsensusHold
Number of Analyst Covering6
Bausch Health Companies News
PremiumCompany Announcements
Bausch Health Wins Patent Appeal for XIFAXAN
Bulls Say, Bears Say
Bulls Say
Financial Health And StrategyBHC's debt levels are expected to be under control, which could allow for the planned spin-off and be positively received by the market.
Legal And Patent StatusFederal Circuit of Appeals Judges issued an affirmance in the Salix v. Norwich Xifaxan lawsuit, maintaining BHC's exclusivity on rifaximin 550mg until 2029.
Market Sentiment And Stock PerformanceQ4 BHC revenue and operating income exceeded analyst forecasts, indicating a stronger financial performance than anticipated.
Bears Say
Corporate StrategyThe path and timeline to the proposed BLCO spin-off remains a key investor focus but no definitive timeline offered.
Financial PerformanceBHC's sales excluding Bausch & Lomb were slightly lower than expected, highlighting a potential area of concern.
Legal IssuesThe Amneal lawsuit is creating an overhang on the stock.
---
Ownership Overview
70.56% Insiders
7.23% Mutual Funds
4.57% Other Institutional Investors
17.63% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BHC FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Currently, no data Available
What is Bausch Health Companies’s market cap?
Currently, no data Available
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is May 02, 2024 which is in 14 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on Feb 22, 2024. The company reported $0.952 earnings per share for the quarter, missing the consensus estimate of $1 by -$0.048.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies pays a Quarterly dividend of $1 which represents an annual dividend yield of N/A. See more information on Bausch Health Companies dividends here
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate is $0.69.
How many shares outstanding does Bausch Health Companies have?
Currently, no data Available
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of $0.952 in its last earnings report, missing expectations of $1. Following the earnings report the stock price went up 7.266%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Among the largest hedge funds holding Bausch Health Companies’s share is Carl Icahn C. It holds Bausch Health Companies’s shares valued at 278M.
---
Bausch Health Companies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.80 (25.95% Upside)
$10.80 (25.95% Upside)
Blogger Sentiment
Bullish
BHC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.48%
Trailing 12-Months
Company Description
Bausch Health Companies
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets.
---
BHC Company Deck
---
BHC Earnings Call
Q4 2024
0:00 / 0:00
---
BHC Revenue Breakdown
44.64% Pharmaceuticals
22.80% Devices
20.52% OTC
10.96% Branded and Other Generics
1.07% Other
---
BHC Stock 12 Months Forecast
Average Price Target
$10.80
▲(25.95% Upside)
Technical Analysis
Best Analysts Covering BHC
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+13.93%
reiterated a sell rating 2 months ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +13.93% per trade.
---